Can a chatbot help prevent opioid overdoses? new pilot study explores telehealth solution
NCT ID NCT05832879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a telehealth platform designed to encourage people with opioid use disorder to start and stay on medication treatment. 33 participants with a history of opioid overdose used the platform, which included chat-based support. The study measured whether they attended their first medication appointment and stayed engaged over 90 days, as well as tracking any further overdose events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telehealth platform (behavioral intervention)
What this could lead to
If successful, this could provide a scalable way to connect people with opioid use disorder to medication treatment and reduce overdose events.
What could go wrong
This is a small pilot study with only 33 participants, so results may not apply broadly. The platform's effectiveness depends on user engagement and access to technology.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States